CryoLife Reports First Quarter 2021 Financial Results News provided by Share this article First Quarter and Recent Business Highlights: Achieved total revenues of $71.1 million in the first quarter 2021 versus $66.4 million in the first quarter of 2020, an increase of 7% on a GAAP basis and 3% on a non-GAAP proforma constant currency basis Net loss was ($3.1) million, or ($0.08) per share, in the first quarter of 2021 Non-GAAP net income was $1.4 million, or $0.03 per share, in the first quarter of 2021 CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its financial results for the first quarter ended March 31, 2021.